Dry Eye

In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.

BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

Ophthalmologists, optometrists gain nonpharmacological treatment options for some of the eye’s most complex issues, providing better outcomes.

Patients are at risk for developing severe dry eye and ocular surface disease.

Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.

The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected.

A team of investigators from Pohang University of Science and Technology has found that conjunctival goblet cell examination is important for the precise diagnosis and effective treatment of ocular surface diseases; however, CGC examination has not been possible until now due to lack of non-invasive devices.

Top-line results are expected during second quarter for the therapeutic to treat patients with dry eye disease.

Cynthia Matossian, MD, shares her thoughts on the premium patient "experience" or "journey," emphasizing the outcomes of patient experiences.

According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Short-term steroid use can alleviate patient discomfort.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

The company expects to have topline proof of concept data by the end of the first quarter of the year.

TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.

Cynthia Matossian, MD, FACS, ABES, points out that there has been confusing news lately about what is (and is not) covered by Medicare when it comes to in-office treatments for meibomian gland dysfunction.

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Moore suffered from dry eye disease and Lumenis noted that treatment with OptiLight improved her condition. Now she’s partnering with the company to share her story and empower others.

The FDA has approved the first generic of cyclosporine ophthalmic emulsion (Restasis; Allergan) 0.05% single-use vials of eye drops to increase tear production in patients with dry eye disease.

A new treatment option may increase basal tear production in patients.

According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.

According to the company, OK-101 displays both anti-inflammatory and ocular pain-reducing potential.

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a triple 8 antagonist, for the treatment of dry eye.

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.